Brief Summary
The aim of this study to assess the feasibility of a diffusion-weighted magnetic resonance imagingtests that create detailed images of areas inside the body (DW-MRI) guided radiotherapy boost for locally advancedat a late stage, far along rectal cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs.
Intervention/Treatment
- Magnetic resonance imaging (MRI).
- Radiation therapya treatment that uses controlled doses of radiation to damage or kill cancer cells.
Inclusion Criteria
- Able to give informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..
- Histologically-proven primary rectal adenocarcinomacancer arising from mucus-producing glands in organs within 0-10cm of anorectal junction on MRI or enteroscopy (T3, T4 or nodea small lump or mass of tissue in your body positive disease with no evidence of metastatic spread (M0) on stagingthe process of determining how big the cancer is, where it started and if it has spread to other areas CT-chest/abdomen/pelvis (i.e. stage II/III disease)).
- Patient undergoing curative intent neoadjuvant radiotherapy +/- chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells:
- Neoadjuvant radiotherapy must be first component of neoadjuvant therapy (i.e. no induction course).
- Concurrent chemotherapy can include capecitabine or fluorouracil.